Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | -400.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.10 | N/A | -400.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions. They did not offer any forward-looking guidance, indicating uncertainty.
Management did not provide specific guidance for future performance.
The company acknowledged challenges faced in the quarter.
Repligen Corp's earnings report showed a significant miss on EPS, leading to a 5.59% drop in stock price. The lack of revenue data and guidance adds to investor uncertainty. The company is facing challenges that may impact future performance, and without clear direction from management, investors may remain cautious.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime